A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles
Authors:
Open Access
- 28 February 2022
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (1) , 1-20
Abstract
Purpose: The neoadjuvant treatment of breast cancer (NABC) is a rapidly changing area that benefits from guidelines integrating evidence with expert consensus to help direct practice. This can optimize patient outcomes by ensuring the appropriate use of evolving neoadjuvant principles. Methods: An expert panel formulated evidence-based practice recommendations spanning the entire neoadjuvant breast cancer treatment journey. These were sent for practice-based consensus across Canada using the modified Delphi methodology, through a secure online survey. Final recommendations were graded using the GRADE criteria for guidelines. The evidence was reviewed over the course of guideline development to ensure recommendations remained aligned with current relevant data. Results: Response rate to the online survey was almost 30%; representation was achieved from various medical specialties from both community and academic centres in various Canadian provinces. Two rounds of consensus were required to achieve 80% or higher consensus on 59 final statements. Five additional statements were added to reflect updated evidence but not sent for consensus. Conclusions: Key highlights of this comprehensive Canadian guideline on NABC include the use of neoadjuvant therapy for early stage triple negative and HER2 positive breast cancer, with subsequent adjuvant treatments for patients with residual disease. The use of molecular signatures, other targeted adjuvant therapies, and optimal response-based local regional management remain actively evolving areas. Many statements had evolving or limited data but still achieved high consensus, demonstrating the utility of such a guideline in helping to unify practice while further evidence evolves in this important area of breast cancer management.Keywords
Funding Information
- Terry Fox Research Institute (1083)
This publication has 104 references indexed in Scilit:
- Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast CancerJAMA Oncology, 2016
- Neoadjuvant dose-dense chemotherapy for locally advanced breast cancerAnti-Cancer Drugs, 2016
- FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy StudiesThe Oncologist, 2016
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialThe Lancet Oncology, 2016
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term OutcomesJAMA Oncology, 2016
- Clinical implications of the intrinsic molecular subtypes of breast cancerThe Breast, 2015
- Neoadjuvant Therapy for Breast Cancer: Controversies in Clinical Trial Design and Standard of CareAmerican Society of Clinical Oncology Educational Book, 2015
- A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and BeyondCurrent Oncology, 2015
- GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strengthJournal of Clinical Epidemiology, 2013
- GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendationsJournal of Clinical Epidemiology, 2013